← Leaderboards
Charles Testa
Echelon Biosciences, Inc.
$13,870,581
Attributed
$13,870,581
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2008–25$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,870,581 · 7
By mechanism
R44$6,999,995 · 3
R01$5,079,521 · 1
R43$1,791,065 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Analog”
- David Heimbrook · Leidos Biomedical Research, Inc.$196,589,777
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Norman Wolmark · Nsabp Foundation, Inc.$51,982,954
- Robert Turner Schooley · University Of Colorado Denver$48,513,949
- Kenneth A Bloom · University Of Nebraska-Lincoln$46,979,168
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
AnalogGram-Negative BacteriaBiochemicalResistancePathogenAnti-Bacterial AgentsBacteriaAntibioticsEscherichia ColiEvaluationInfectionIn VitroResistant StrainLeadPre-ClinicalDoseIndexingIn VivoBacterial ProteinsDrug KineticsFrequenciesBindingBinding ProteinsEngineering
Grant awards (18)
New oral antibiotics focused on treating MDR Gram-negative infections$1,000,000
R44 · FY2025 · AI · contact PI
A new class of antibiotic to address Antimicrobial Resistance$999,997
R44 · FY2025 · AI · contact PI
New oral antibiotics focused on treating MDR Gram-negative infections$1,000,000
R44 · FY2024 · AI · contact PI
A new class of antibiotic to address Antimicrobial Resistance$999,998
R44 · FY2024 · AI · contact PI
A new class of broad-spectrum antibacterials for treating MDR infections$1,000,000
R44 · FY2022 · AI · contact PI
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome$1,045,564
R01 · FY2021 · AI · contact PI
A new class of broad-spectrum antibacterials for treating MDR infections$1,000,000
R44 · FY2021 · AI · contact PI
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome$1,193,671
R01 · FY2020 · AI · contact PI
A new class of broad-spectrum antibacterials for treating MDR infections$1,000,000
R44 · FY2020 · AI · contact PI
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome$1,206,566
R01 · FY2019 · AI · contact PI
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome$766,731
R01 · FY2018 · AI · contact PI
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome$866,989
R01 · FY2017 · AI · contact PI
Natural product-inspired antibacterials with unique ribosomal binding$298,770
R43 · FY2017 · AI · contact PI
Natural product-inspired antibacterials with unique ribosomal binding$300,000
R43 · FY2016 · AI · contact PI
Methylerythritol Phosphate Pathway-Specific Natural Products as Antibacterials$300,000
R43 · FY2009 · AI · contact PI
Methylerythritol Phosphate Pathway Inhibitors Targeting Gram-Negative Infections$299,834
R43 · FY2009 · AI · contact PI
Methylerythritol Phosphate Pathway Inhibitors Targeting Gram-Negative Infections$300,000
R43 · FY2008 · AI · contact PI
Methylerythritol Phosphate Pathway-Specific Natural Products as Antibacterials$292,461
R43 · FY2008 · AI · contact PI